1029P Two-year follow-up from KN046 in combination with platinum doublet chemotherapy as first-line (1L) treatment for NSCLC: An open-label, multi-center phase II trial

Y Zhao,G Chen,X Li,J Wu,B Chang,S Hu,S Yang,Y Liu,N Wang,Y Huang,L Zhang

doi:10.1016/j.annonc.2022.07.1155

1029P Two-year follow-up from KN046 in combination with platinum doublet chemotherapy as first-line (1L) treatment for NSCLC: An open-label, multi-center phase II trial

Y Zhao, G Chen + Show 9 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.1155

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

Affiliation: Sun Yat-sen University Cancer Center, First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Xiamen University, First Affiliated Hospital of Henan University of Science and Technology, Henan Cancer Hospital

#Advanced NSCLC Pts #Platinum Doublet Chemotherapy + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

KN046 is a novel bispecific domain antibody, which blocks both PD-L1 and CTLA-4. Primary analysis of this phase II trial (data as of January 19, 2021) showed promising efficacy and well tolerated safety in advanced NSCLC pts. Herein, we present an updated analysis.

Full Text